Loading
Histone Deacetylase Inhibitors Research / Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Onco · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes the role of epigenetic dysregulation in ovarian cancer drug resistance and proposes nanotechnology-based delivery systems as a potential solution to overcome limitations of existing epigenetic agents. No original data, clinical trials, or empirical results are reported; the work presents a conceptual framework and identifies translational barriers for future clinical development.
Journal article. Patients with ovarian cancer (target population discussed, not studied).
Epigenetic mechanisms contribute to ovarian cancer drug resistance and dysregulated modifications are key contributors. Current epigenetic agents (DNA methyltransferase inhibitors, histone deacetylase inhibitors, non-coding RNA therapeutics) have limitations including poor water solubility, limited tissue distribution, low stability, and systemic toxicity. Nanotechnology offers encapsulation strategies to increase bioavailability, enhance cellular internalization, reduce drug dose and toxicity, and enable tumor-targeted delivery.
No clinical trial data, efficacy metrics, or safety outcomes reported. Current epigenetic agents (DNA methyltransferase inhibitors, histone deacetylase inhibitors, non-coding RNA therapeutics) have limitations including poor water solubility, limited tissue distribution, low stability, and systemic toxicity.
This review identifies a therapeutic gap and conceptual opportunity but does not provide evidence-based guidance for current clinical practice. Clinicians should recognize nanotechnology-based epigenetic therapy as an emerging, preclinical-to-translational concept requiring substantial further development before clinical adoption.
A narrative review synthesizing mechanistic evidence and preclinical nanotechnology concepts without reporting original clinical or experimental data, endpoints, or comparisons.
This review identifies a therapeutic gap and conceptual opportunity but does not provide evidence-based guidance for current clinical practice. Clinicians should recognize nanotechnology-based epigenetic therapy as an emerging, preclinical-to-translational concept requiring substantial further development before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Epigenetic mechanisms play a crucial role in OC drug resistance, and emerging evidence suggests that dysregulated epigenetic modifications are among the key contributors to OC. Epigenetic agents, including DNA methyltransferase inhibitors, histone deacetylase inhibitors, and non-coding RNA-based therapeutics, have important limitations, including poor water solubility, limited tissue distribution, low stability, and systemic toxicity. To overcome this, a novel drug delivery system is needed to manage variability in drug administration and maximize the efficacy of these drugs. In this regard, nanotechnology offers an attractive option for formulating epigenetic drugs with various encapsulation strategies to increase bioavailability and drug efficacy, reduce drug dose, administration frequency, and toxicity, and enhance cellular internalization and tumor-targeted delivery. In this review, we summarize various epigenetic regulators and their roles in OC therapy resistance as well as the development of nanosystems for epigenetic drug delivery, which could lay the foundation for designing nanoformulations encapsulating epigenetic therapeutics, ultimately advancing personalized, targeted therapy for patients with OC. This review also discusses the current clinical status of nanocarrier platforms and translational barriers that limit the clinical development of epigenetic nanomedicine, highlighting the future directions required for successful clinical translation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.